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Abstract
Pathological cardiac overload induces myocardial protein synthesis
and hypertrophy, which predisposes to heart failure. To inhibit
hypertrophy therapeutically, the identification of negative regula-
tors of cardiomyocyte protein synthesis is needed. Here, we identi-
fied the tumor suppressor protein TIP30 as novel inhibitor of
cardiac hypertrophy and dysfunction. Reduced TIP30 levels in mice
entailed exaggerated cardiac growth during experimental pressure
overload, which was associated with cardiomyocyte cellular hyper-
trophy, increased myocardial protein synthesis, reduced capillary
density, and left ventricular dysfunction. Pharmacological inhibi-
tion of protein synthesis improved these defects. Our results are
relevant for human disease, since we found diminished cardiac
TIP30 levels in samples from patients suffering from end-stage
heart failure or hypertrophic cardiomyopathy. Importantly, thera-
peutic overexpression of TIP30 in mouse hearts inhibited cardiac
hypertrophy and improved left ventricular function during pres-
sure overload and in cardiomyopathic mdx mice. Mechanistically,
we identified a previously unknown anti-hypertrophic mechanism,
whereby TIP30 binds the eukaryotic elongation factor 1A (eEF1A)
to prevent the interaction with its essential co-factor eEF1B2 and
translational elongation. Therefore, TIP30 could be a therapeutic
target to counteract cardiac hypertrophy.
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Introduction
Pathological cardiac hypertrophy, which predisposes to the develop-
ment of heart failure, frequently develops as consequence of ventricu-
lar pressure overload, myocardial infarction or due to inherited
cardiomyopathy (Heineke & Molkentin, 2006; Hill & Olson, 2008). It is
associated with decreased cardiac function, increased cardiomyocyte
size, interstitial fibrosis, and capillary rarefaction (Hein et al, 2003).
Many signaling proteins were identified that act in concert to trigger
transcription of a pro-hypertrophic gene program (Heineke & Molk-
entin, 2006; Hill & Olson, 2008). This gene program entails mainly
qualitative changes in gene expression, but does not account for the
quantitative changes during cardiac growth, which are characterized
by strong accumulation of newly synthesized proteins that can lead to
enlargement of the heart by more than 50% (Nagatomo et al, 1999;
McDermott et al, 2012). The strong increase in cardiac protein content
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mainly results from enhanced protein synthesis within the first 1–
5 days of pressure overload with or without a significant decrease in
protein degradation (Nagatomo et al, 1999; McDermott et al, 2012).
After 10–14 days, hypertrophy reaches its maximum and a new steady
state is attained, in which protein synthesis equals protein degradation
and cardiac mass remains stable (Nagatomo et al, 1999). mTOR as
catalytic subunit of the mTOR containing multiprotein complex 1
(mTORC1) promotes cardiac protein synthesis and hypertrophy mainly
by fostering translational initiation (Laplante & Sabatini, 2012).
mTORC1 inhibition by rapamycin or its partial deletion in zebrafish
improves cardiac function, although its complete genetic abrogation in
cardiomyocytes induces cardiomyopathy (Shioi et al, 2003; McMullen
et al, 2004; Ma & Blenis, 2009; Ding et al, 2011; Zhang et al, 2011b).
As overgrowth of the myocardium is associated with poor prognosis
during disease (Levy et al, 1990), the identification of currently largely
undefined endogenous negative regulators of hypertrophy at the level
of cardiomyocyte protein synthesis might reveal interesting future ther-
apeutic targets, especially when their abundance is dysregulated in fail-
ing hearts.
Protein synthesis is a tightly regulated process that is initiated at the
start codon by the 80S ribosome and continues into elongation wherein
the peptide chain increases its length cyclically one amino acid at a
time (Sasikumar et al, 2012). Translational elongation is catalyzed by
the eukaryotic translation elongation factor 1A (eEF1A), which in its
active GTP-bound form binds and delivers amino acid loaded tRNAs to
the A-site of the ribosome. By formation of the correct codon–anti-
codon pair between tRNA and mRNA, a conformational change in the
ribosome leads to GTP hydrolysis and release of then inactive, GDP-
bound eEF1A. GDP needs to be actively exchanged for GTP by the
guanine nucleotide exchange factor (GEF) eEF1B2, in order to enable
eEF1A to participate in another round of elongation.
Here, we characterized the 30 kDa protein TIP30 (also termed
Htatip2) as inhibitor of mRNA translation and cardiac hypertrophy
and revealed that it protects against heart failure during pathological
stimulation. TIP30 is ubiquitously expressed and is acting as tumor
suppressor, since reduced TIP30 levels were found in human cancers
and were related to enhanced tumor growth and metastasis forma-
tion (Shtivelman, 1997; Ito et al, 2003; Zhao et al, 2007; Li et al,
2009). Moreover, homozygous (Tip30/, KO) and heterozygous
(Tip30+/, Het) Tip30 knock-out mice develop malignant tumors
starting at 18–20 months of age (Ito et al, 2003; Li et al, 2013; Chen
et al, 2014). The role of TIP30 in the heart, however, had so far not
been analyzed. TIP30 is well conserved across species, and crystallo-
graphic analyses suggest binding of NADPH, but found enzymatic
activity of TIP30 to be very unlikely (El Omari et al, 2005). Instead,
it was suggested that TIP30 might play a regulatory role by mediating
protein interactions (El Omari et al, 2005; Nakahara et al, 2009).
Accordingly, we demonstrate here that TIP30 interacts with eEF1A
to prevent association with its co-factor eEF1B2, thereby blocking
translational elongation and cardiomyocyte hypertrophy.
Results
TIP30 deficiency facilitates cardiac hypertrophy and failure
To assess the functional role of TIP30 during cardiac overload, we
subjected heterozygous (Het, with a 50–60% reduction of cardiac
TIP30) and homozygous Tip30 knock-out (KO, completely deficient
of TIP30) as well as wild-type (WT) mice to sham or transverse
aortic constriction (TAC) surgery (Fig 1A). While no phenotypic dif-
ferences were noted after sham operation, Het and KO mice devel-
oped more cardiac hypertrophy (i.e., increased heart weight/tibia
length ratio, HW/TL; Fig 1B) 6 weeks after TAC surgery. Het, but
not KO or WT mice exerted enhanced pulmonary congestion (in-
creased lung weight/TL; Fig 1C) as sign of cardiac dysfunction after
TAC. Accordingly, echocardiography revealed decreased cardiac
systolic function (fractional area change) in Het mice and increased
cardiac dilation (LVEDA) in Het and KO mice versus WT mice
6 weeks after TAC (Fig 1D and E). Increased dilation and wall thick-
ness of the left ventricle (indicative of enhanced hypertrophy), as
well as cardiac dysfunction, were already observed in Het (but not
KO) versus WT mice 2 weeks after TAC in echocardiography
(Fig EV1A–D). Because Het mice therefore showed a more promi-
nent phenotype than KO mice, we carried out most of the following
experiments in Het in comparison with WT mice. To rule out princi-
pal differences in the degree of pressure overload after TAC between
both genotypes, we conducted Doppler measurements of right
versus left carotid artery blood flow. The results indicated that a
similar degree of left ventricular pressure overload was reached in
Het and WT mice 2 days after TAC versus sham surgery
(Fig EV1E).
Direct analysis of left ventricular pressure development by
catheterization revealed decreased left ventricular contractility (dP/
dt max), relaxation (dP/dt min), and systolic pressure in Het versus
WT mice during pressure overload (Figs 1F and G, and EV1F).
Single cardiomyocyte contractility, however, was not different
between WT and Het cardiomyocytes after TAC at three different
pacing rates (Fig EV1G). Six weeks after TAC surgery, we found a
similarly reduced expression of a-myosin heavy chain (a-MHC), but
significantly more increased b-MHC expression in the myocardium
of Het mice (Fig 1H and I). Cardiac fibrosis was not different
between the experimental groups (Fig 1J and K), and accordingly,
the number of PDGFRa-positive cardiac fibroblasts was also not
changed between them (Fig EV1H and I). In line with the increased
HW/TL ratio, enlarged cardiomyocytes were found in Het versus
WT mice after TAC (Fig 1L). This augmented cardiomyocyte growth
was not accompanied by growth of the cardiac micro-vasculature,
since we detected a prominent reduction of the capillary/cardiomy-
ocyte ratio selectively in Het mice after TAC (Fig 1M and N). As
capillary rarefaction during pressure overload is known to be
maladaptive, it might at least partially contribute to cardiac dysfunc-
tion in Het mice during TAC (Heineke et al, 2007; Sano et al, 2007;
Heineke, 2012). In contrast to capillary density, the rate of apoptotic
(i.e., cleaved caspase 3 positive) cardiomyocytes was not different
between WT and Het mice (Fig EV1J). Profiling of the myocardium
of WT and Het mice after TAC by electron microscopy excluded
gross ultrastructural defects in these mice (Fig EV1K).
We next analyzed whether increased hypertrophy in Tip30 Het
mice was the result of TIP30 deficiency primarily in cardiomyocytes,
as these mice have systemically reduced TIP30 levels. Aggravated
cardiac hypertrophy and pulmonary congestion in Het mice after
TAC were reversed upon mild cardiomyocyte specific overexpres-
sion of TIP30 by a highly cardiomyocyte selective troponin T
promoter-dependent AAV9 vector (AAV9-TropT-TIP30; Figs 1O–R,
and EV1L and M; Werfel et al, 2014), indicating that lack of TIP30
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in cardiomyocytes of Het mice is predominantly contributing to the
observed phenotype in these mice.
Next, we assessed the impact of TIP30 on heart growth during
homeostatic conditions: With increasing age, 7-month-old Tip30 Het
mice developed enhanced hypertrophy (indicated by an increased
HW/TL ratio, an increased wall thickness in echocardiography, and
an increased cardiomyocyte area in histological sections) versus WT
mice without any additional stress stimulation, but this was not
associated with cardiac dysfunction or dilatation (Fig EV2A–G).
Reduced myocardial mTORC1 activation in Tip30 Het mice
Because we observed enhanced cardiac growth in Tip30 Het mice
during pathological stimulation and with increasing age, we
analyzed different cell growth-related signaling pathways in the
myocardium of WT and Het mice 6 weeks after sham or TAC
surgery. We detected a decreased activation of pro-hypertrophic
mTORC1 in Het mice after TAC, which was reflected by markedly
reduced levels of p70S6Kinase phosphorylation, reduced mTOR
phosphorylation and to a lesser extent 4E-BP1 phosphorylation
(Fig EV3A and B). A reduction in p70S6K phosphorylation was even
visible in Het versus WT mice after sham surgery. The decrease in
mTORC1 activation in the myocardium of Het mice was counterintu-
itive, because these mice showed more heart growth, and we
therefore propose that this was a secondary phenomenon to limit the
increased protein synthesis that we detected in the myocardium of
Het mice (see below). In addition, the decreased activation of ERK1/
2 as well as the increased AMPK activation in the myocardium of Het
mice after TAC might directly contribute to reduced mTOR activity
in Het mice (Wullschleger et al, 2006). The activation and/or abun-
dance of other growth-signaling pathways (p38/JNK-MAPK, eEF2,
Akt) was not significantly changed between WT and Het mice.
TIP30 overexpression restricts cardiac hypertrophy and improves
heart function
Neonatal rat cardiomyocytes (NRCM) are widely used as model
system to study cardiac hypertrophy. Stimulation of NRCM with the
pro-hypertrophic growth factors phenylephrine (PE), fetal bovine
serum (FBS), or endothelin-1 (ET-1) led to a mild (about twofold)
induction of TIP30 protein levels (Appendix Fig S1A). Since reduced
Tip30 expression in Het mice led to increased cardiac hypertrophy,
we wanted to assess whether TIP30 overexpression could inhibit
this response. We used a recombinant adenovirus to overexpress
TIP30 (Ad.TIP30) in NRCM (Fig 2A). When stimulated with ET-1 or
PE, Ad.TIP30 markedly reduced the increase in cell size compared
to Ad.Control-treated NRCM and the same trend was observed
during FBS stimulation (Fig 2B). Overexpression of TIP30 also
◀ Figure 1. TIP30 deficiency results in enhanced cardiac hypertrophy during pathological overload.A Schematic representation of the study design and Western blot analysis for TIP30 and GAPDH in hearts from TIP30 wild-type (WT), heterozygous (Het), and
homozygous knock-out (KO) mice under basal conditions.
B–I Quantification of heart weight (HW)/tibia length (TL) ratio (B), lung weight (LuW/TL) ratio (C), echocardiographic fractional area change (D) and left ventricular
end-diastolic area (LVEDA; E), dP/dt max and dP/dt min (Millar catheter; F, G), and a-MHC and b-MHC transcript abundance (H, I). N = 4–18 mice/group, all
6 weeks after TAC or sham surgery. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. One-way ANOVA with Sidak’s multiple comparisons test.
J, K Representative images of Sirius red-stained heart sections (scale bar: 1 mm) (J) and fibrosis quantification (K) of indicated mice 6 weeks after TAC or sham surgery.
N = 3-5 mice/group.
L Quantification of cardiomyocyte area of isolated adult cardiac myocytes (N = 4–11 mice/group) of indicated mice 6 weeks after TAC or sham surgery. *P < 0.05.
One-way ANOVA with Sidak’s multiple comparisons test.
M, N Microscopy images of heart sections of indicated mice 6 weeks after TAC surgery stained for isolectin B4 (green) and WGA (red, M) and quantification of capillaries
per myocyte (N). (N = 5–7 mice/group, scale bar: 50 lm). **P < 0.01. One-way ANOVA with Sidak’s multiple comparisons test.
O Schematic representation of AAV-TopT-TIP30 study design.
P Western blot analysis for TIP30 and GAPDH in hearts from TIP30 wild-type (WT) and heterozygous (Het) after AAV-TropT-TIP30 or AAV-control (AAV-Con) injection
followed by 6 weeks of TAC surgery.
Q, R Quantification of HW/TL ratio (Q) and LuW/TL (R) ratio in AAV-Con or AAV-TropT-TIP30 treated Tip30 heterozygous (Het) or WT mice 6 weeks after TAC or sham
surgery (N = 5–11 mice/group). *P < 0.05, ***P < 0.001. One-way ANOVA with Sidak’s multiple comparisons test.
Data information: Data are shown as mean  SEM.
Source data are available online for this figure.
▸Figure 2. TIP30 overexpression inhibits cardiac hypertrophy.A Western blot for TIP30 and GAPDH in neonatal rat cardiomyocytes (NRCM) after adenoviral transduction with Ad.Control (Ad.Con) or Ad.TIP30.
B–E Quantification of cardiomyocyte area, N = 6–8 samples/group (B), protein/DNA ratio, N = 9 samples/group (C), Acta1 mRNA transcript abundance, N = 3
samples/group (D), and cell death with a 7-AAD assay, N = 7 samples/group (E) in NRCM transduced with Ad.Con or Ad.TIP30 and stimulated as indicated. ET-1:
endothelin-1, FBS: fetal bovine serum, PE: phenylephrine. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. One-way ANOVA with Sidak’s multiple
comparisons test.
F Schematic representation of AAV-MLC-TIP30 study design.
G Western blot for TIP30 and Actin in mouse hearts with AAV9 mediated overexpression of TIP30 (AAV-TIP30) or from mice treated with a control AAV9 construct
(AAV-Con) followed by 2 weeks of TAC surgery.
H, I Quantification of HW/TL ratio, N = 8–13 mice/group (H) and cardiomyocyte area, N = 4–5 mice/group (I) 2 weeks after sham or TAC surgery in AAV-Con or AAV-
TIP30-treated C57BL/6 WT mice. *P < 0.05. One-way ANOVA with Sidak’s multiple comparisons test.
J Serial echocardiography with quantification of echocardiographic fractional area change 2, 4, and 6 weeks after sham or TAC surgery in AAV-Con or AAV-TIP30-
treated C57BL/6 WT mice (N = 10–14 mice/group and time point). **P < 0.01. One-way ANOVA with Sidak’s multiple comparisons test.
Data information: Data are shown as mean  SEM.
Source data are available online for this figure.
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blunted the increase in cellular protein content (measured as
protein/DNA ratio) in response to PE and the expression of the
hypertrophic marker gene Acta1 during ET-1 or PE stimulation
(Fig 2C and D). Because TIP30 overexpression was reported to
induce cell death in cancer models (Xiao et al, 2000), we analyzed
whether TIP30 acts similarly in cardiomyocytes. However,
cardiomyocyte death (assessed by 7-AAD staining) was not
enhanced by TIP30 overexpression with or without PE stimulation
(Fig 2E). Next, we analyzed the effects of cardiac TIP30 overexpres-
sion (via AAV9 vector, containing a modified myosin-light chain
A B C
D E F
G H I
J
Figure 2.
ª 2019 The Authors EMBO Molecular Medicine 11: e10018 | 2019 5 of 20
Andrea Grund et al EMBO Molecular Medicine
promoter) in WT mouse hearts in vivo (Fig 2F and G). In line with
the results from NRCM, transduction with AAV-TIP30 blunted the
increase in heart and cardiomyocyte hypertrophy visible in AAV-
control-treated mice in response to 2 weeks of TAC (Fig 2H and I).
Serial echocardiography revealed a sustained improvement of
systolic cardiac function in AAV-TIP30-treated mice 2, 4, and
6 weeks after TAC surgery (Fig 2J). Interrogation of growth signal-
ing in hearts or isolated cardiomyocytes with TIP30 overexpression
did not reveal any significant effects during hypertrophic stimula-
tion (Appendix Fig S1B and C).
TIP30 binds eEF1A
In order to elucidate the molecular mechanisms that underlie the
anti-hypertrophic effect of TIP30, we screened for TIP30 interacting
proteins by GST-pulldown assay from NRCM. A number of proteins
enriched in the GST-TIP30 versus the GST-pulldown (identified by
mass spectrometry) were at least partially associated with the trans-
lational apparatus: nucleolin (Ncl), eEF1A1, heterogeneous nuclear
ribonucleoprotein (hnRNP)A2/B1, and ribosomal protein (Rp)S3a
(Appendix Table S1). We verified the interaction of these proteins
with TIP30 in a GST-pulldown assay with GST-TIP30 constructs of
different length (Fig 3A). All identified proteins interacted with full-
length TIP30. While the first N-terminal 230 amino acids of TIP30
(total length: 242 amino acids) were necessary for interaction with
Ncl and Rps3a, only the first 50 amino acids were needed to interact
with eEF1A1, and full-length TIP30 was required for binding to
hnRNPA2/B1.
We subsequently focused on the interaction between eEF1A1 and
TIP30. We hypothesized that TIP30 exerts its anti-hypertrophic
effects by interfering with eEF1A1 and by inhibiting protein synthesis
during translational elongation. The interaction of both proteins was
verified by co-immunoprecipitation of GST-tagged TIP30 full-length
protein with Myc-tagged eEF1A1 (Fig 3B). Endogenous TIP30 and
eEF1A1 partially co-localized in cardiomyocytes as shown by
immunofluorescence staining (Fig 3C). We employed a proximity
ligation assay to more directly assess the interaction of both proteins
in situ. As demonstrated in Fig 3D, endogenous TIP30 interacted
with eEF1A1 (each interaction is indicated by a red dot). Endogenous
TIP30 and eEF1A1 were also co-immunoprecipitated from NRCM
(Fig 3E). A pulldown assay with GST-eEF1A1 showed that the N-
terminal 25 amino acids of TIP30 (as part of its NADPH binding
domain) are necessary for eEF1A1 binding (Fig 3F–H). In turn, a
pulldown assay with GST-TIP30 revealed that recombinant eEF1A1
lacking the middle domain, which is important for eEF1B binding,
could not bind TIP30, while domains one or three were not essential
for binding (Fig 3I).
Beside the ubiquitous eEF1A1, the heart also expresses its
isoform eEF1A2 (Chambers et al, 1998). While eEF1A1 mRNA and
protein were reduced after birth in the heart as previously reported,
we found that it is strongly re-induced in the adult myocardium in
response to TAC (Fig 3J and K). In contrast, eEF1A2 mRNA and
protein were markedly induced in the adult compared to neonatal
hearts, but remained unchanged after TAC. A GST-TIP30 pulldown
revealed that TIP30 also interacts with eEF1A2, the isoform of
eEF1A mainly expressed in adult myocardium (Fig 3L).
TIP30 inhibits the interaction of eEF1A1 with its co-factor eEF1B2
Next, we elucidated the consequences of the interaction between
TIP30 and eEF1A. eEF1A binds tRNAs and delivers amino acids to
the A-site of the ribosome during protein synthesis. To fulfill this
function, eEF1A binds eEF1B2 and exists in its GTP-bound form
(Pittman et al, 2009). Inactive, GDP-bound eEF1A is recycled to the
active form by the GEF eEF1B2. Because TIP30 binds eEF1A1 in its
middle region where also eEF1B2 binds (Fig 3I), we analyzed
whether TIP30 affects the interaction between eEF1A1 and eEF1B2.
Increasing concentrations of recombinant TIP30 decreased binding
between eEF1A1 and eEF1B2 in a GST-pulldown assay (Fig 4A).
Similarly, overexpression of TIP30 in PE-stimulated isolated
▸Figure 3. TIP30 interacts with eEF1A.A Western blot analysis of GST-pulldown assays with GST-TIP30 fragments of the indicated length (as amino acids from N-terminus) with Myc-tagged binding
partners. Red asterisks indicate isolated GST-TIP30 fusion proteins.
B Western blot analysis of co-immunoprecipitation (IP) from HEK cells transfected with GST-TIP30 and eEF1A1-Myc.
C Confocal microscopy images of neonatal rat cardiomyocytes (NRCM) stained with antibodies for endogenous TIP30 (green) and endogenous eEF1A1 (red). DAPI:
blue (scale bar: 20 lm).
D Microscopy images of isolated neonatal rat cardiomyocytes and subsequent proximity ligation assay (PLA). Red: endogenous TIP30/eEF1A1 interaction; Blue: DAPI.
Control cells were stained for TIP30/Myc-tag interaction (scale bar: 50 lm).
E Western blot analysis of co-immunoprecipitation (IP) for endogenous TIP30 and eEF1A1 protein in NRCM after stimulation with phenylephrine for 24 h. IgG HC—
high chain of IgG molecule.
F Scheme showing the structure of TIP30-His deletion mutants that were used in GST-pulldown assays in (G). The C-terminal His-tag is highlighted in blue.
G, H Western blot analysis of GST-pulldown assays with GST or GST-tagged eEF1A1 (GST-eEF1A1) and TIP30-His full-length protein (TIP30-His) and TIP30 deletion
mutants DN25 (TIP30-DN25-His), DN52 (TIP30-DN52-His), DC15 (TIP30-DC15-His), and D102-107 (TIP30-DN102-104-His, G) and Western blot analysis of GST-
tagged eEF1A1 and GST-control (H).
I Scheme depicting eEF1A domains, their different binding patterns for GDP/GTP or eEF1B2 and the His-tagged eEF1A1 mutants. Western blot analysis of GST-
pulldown assays with GST-TIP30 and the indicated His-tagged eEF1A1 mutants are shown.
J Quantitative real-time PCR analysis of eEF1A1 and eEF1A2 mRNA abundance in hearts from neonatal mice, adult wild-type mice (adult) and adult wild-type mice
2 weeks after TAC surgery (adult TAC, N = 3–4 mice/group). *P < 0.05, ***P < 0.001. One-way ANOVA with Sidak’s multiple comparisons test.
K Western blot analysis for eEF1A1, eEF1A2, and GAPDH in hearts from wild-type mice at the age of 7 days (7 d) and 8 weeks (8 w) as well as 2 weeks (TAC 2 w)
after TAC surgery.
L Western blot analysis of co-immunoprecipitation (IP) with GST-TIP30 and eEF1A2-His.
Data information: Data are shown as mean  SEM.
Source data are available online for this figure.
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Figure 4. TIP30 inhibits the interaction of eEF1A1 with its essential co-factor eEF1B2.
A Western blot analysis of GST-pulldown assays with GST or GST-eEF1A1 and purified eEF1B2-His. Purified TIP30-His was added in indicated amounts.
B Western blot analysis of anti-Myc immunoprecipitation (IP) in NRCM co-transduced with Ad.eEF1A1-Myc and either control virus (Ad.con) or Ad.TIP30. Endogenous
eEF1B2 was detected. The IP input for eEF1B2, eEF1A1-myc, and TIP30 is shown below.
C Quantification of eEF1B2 abundance after eEF1A1-myc IP under conditions shown in (B) (N = 3 IP’s/group). *P < 0.05. Two-sided Student’s t-test.
D Microscopy images of NRCM after adenoviral transduction with Ad.TIP30 or control virus (Ad.Con) and stimulation with phenylephrine (PE) and subsequent proximity
ligation assay (PLA). Red: eEF1A1-eEF1B2 interaction; Blue: DAPI (scale bar: 50 lm).
E Quantification of eEF1A1-eEF1B2 interaction in conditions described in (D) (N = 3–4 samples/group). ****P < 0.0001. One-way ANOVA with Sidak’s multiple
comparisons test.
F Microscopy images of adult mouse cardiomyocytes isolated from hearts 3 days (d) after TAC or sham surgery and subsequent PLA. Red: eEF1A1-eEF1B2 interaction;
Blue: DAPI (scale bar: 100 lm). Inserts represent high magnification of the indicated areas.
G Quantification of eEF1A1-eEF1B2 interaction in adult mouse cardiomyocytes isolated from hearts 3 days after TAC or sham surgery and subsequent PLA (N = 4–6
mice/group). *P < 0.05. One-way ANOVA with Sidak’s multiple comparisons test.
Data information: Data are shown as mean  SEM.
Source data are available online for this figure.
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cardiomyocytes decreased binding of eEF1B2 to eEF1A1, which
instead bound TIP30 under these circumstances (Fig 4B and C). In
contrast, TIP30 did not affect tRNA binding by eEF1A1
(Appendix Fig S2). We employed a proximity ligation assay to
assess the interaction of endogenous eEF1A1 and eEF1B2 in
cardiomyocytes in situ. While little interaction was seen in unstimu-
lated cells, pro-hypertrophic stimulation with PE strongly increased
binding between both proteins. Strikingly, overexpression of TIP30
completely inhibited increased binding between eEF1A1 and eEF1B2
during PE stimulation (Fig 4D and E). Accordingly, the eEF1A1-
eEF1B2 interaction was enhanced by 3 days of TAC treatment in
adult cardiomyocytes of WT mice, but was even more exaggerated
in cardiomyocytes from Het mice 3 days after TAC (Fig 4F and G).
Therefore, the interaction between eEF1A1 and its GEF eEF1B2
increased during hypertrophic stimulation (enabling more transla-
tionally active eEF1A1) and this was even more facilitated by
reduced TIP30 levels. In turn, elevated TIP30 levels interfered with
eEF1A-eEF1B2 binding and thus inhibited recycling of GDP-bound
eEF1A to its translationally active GTP-bound form.
A stable ratio of TIP30/eEF1A1 abundance is maintained
in the myocardium during homeostasis and compensated
overload, but is reduced in advanced heart failure and
hypertrophic cardiomyopathy
Because TIP30 exerts an inhibitory role on eEF1A1 during transla-
tional elongation (by interfering with eEF1B2 binding), we analyzed
the abundance of TIP30 in relation to eEF1A1 levels. The TIP30/
eEF1A1 ratio was maintained at 1 in a rather stable manner after
sham surgery as well as 3 days (Fig 5A and B), 2 weeks (Fig 5C
and D), and 6 weeks after TAC (Fig 5E and F) in hearts of WT mice.
While neither TIP30 nor eEF1A1 were significantly regulated 3 days
and 6 weeks after TAC, eEF1A1 levels increased significantly
2 weeks after TAC (versus sham), which was accompanied by a
significant increase in TIP30 levels. The cardiac TIP30/eEF1a1 ratio
naturally dropped below 1 in TIP30 Het mice after sham and TAC
surgery, due to reduced TIP30 levels and virtually unchanged
eEF1A1 abundance (Fig 5G and H). When linking the TIP30/eEF1A1
ratios to the degree of cardiac hypertrophy and function during pres-
sure overload (see Fig 1), one could infer that a ratio around 1
might allow the development of moderate hypertrophy with
compensated heart function, while a ratio < 1 could enable exagger-
ated hypertrophy and cardiac dysfunction, presumably because of
disinhibition of eEF1A1 due to reduced TIP30 levels. By overexpres-
sion of TIP30 via AAV-TIP30, the TIP30/eEF1A1 ratio was increased
(Fig 5I and J), which led to reduced cardiac hypertrophy and
improved heart function after TAC (Fig 2).
To analyze the TIP30/eEF1A1 ratio in human heart failure, we
assessed myocardial mRNA levels of TIP30 and eEF1A1, because
TIP30 protein could not be quantified in human samples due to the
lack of a specific antibody. The TIP30/eEF1A1 ratio was strongly
reduced in human failing hearts (with ischemic or dilated cardiomy-
opathy) as well as in human hearts from patients with hypertrophic
cardiomyopathy (Fig 6A and B, Appendix Table S2). Mice with
muscular dystrophy due to the mdx mutation in the dystrophin gene
serve as model of human cardiomyopathy. Similar as in human
cardiomyopathy, we found a strongly reduced myocardial abun-
dance of TIP30 mRNA and protein and a markedly reduced TIP30/
eEF1A1 ratio in the myocardium of 6-month-old mdx mice (Fig 6C,
Appendix Fig S3A). To test whether elevation of the TIP30/eEF1A1
ratio could improve cardiomyopathy, we administered AAV-TIP30
to mdx mice. AAV-TIP30-treated mdx mice exerted a significantly
reduced left ventricular wall thickness 3 and 9 months after AAV
administration versus AAV-control-treated mice (Fig 6D and E).
Consistent with reduced wall thickness, the AAV-TIP30-treated mdx
mice exerted a significantly lower HW/TL ratio as sign of amelio-
rated cardiac hypertrophy at the age of 9 months (Fig 6F). Cardiac
ejection fraction was unchanged, presumably because beside hyper-
trophy, cell death and fibrosis also contribute to cardiac dysfunction
in mdx mice, but are not addressed by AAV-TIP30 (Yue et al, 2003;
Bostick et al, 2012; Schinkel et al, 2012). Still, AAV-TIP30, but not
AAV-control-treated mice increased cardiac contractility (Ees, end-
systolic elastance, assessed by Millar catheterization) during stimu-
lation with dobutamine (Appendix Fig S3B and C). Although the
association of the TIP30/eEF1A1 ratio with the degree of cardiac
hypertrophy is in line with our hypothesis, it should be emphasized
that a variety of other variables affect the outcome of hypertrophy
(e.g., the presence or absence of additional hypertrophic stimuli, the
genetic background, and age).
TIP30 negatively regulates protein synthesis
Because TIP30 interferes with eEF1A1, we hypothesized that it inhi-
bits peptide chain elongation during protein synthesis. When we
measured protein synthesis by determining incorporation of the
exogenously added aminoacyl-tRNA analogue puromycin into
newly synthesized proteins after 3 h of pro-hypertrophic stimulation
with PE in isolated cardiomyocytes, we found a markedly increased
incorporation of puromycin in cells transduced with Ad.Control,
which was strongly reduced in Ad.TIP30-treated cardiomyocytes
(Fig 7A and B). This confirmed protein synthesis inhibition by
TIP30 overexpression. Polysome profiling from isolated cardiomy-
ocytes showed enhanced polysome formation due to PE stimulation
in Ad.Control-infected cells (Fig EV4A and B). Overexpression of
◀ Figure 5. A stable TIP30/eEF1A1 ratio is maintained in homeostasis and compensated growth conditions.A–F Western blot analysis for TIP30, eEF1A1, and GAPDH in C57BL/6 WT mice 3 days, N = 4 mice/group (A, B), 2 weeks, N = 4–8 mice/group (C, D), and 6 weeks,
N = 4–8 mice/group (E, F) after TAC or sham surgery and their quantification. KO denotes TIP30 homozygous knock-out.
G, H Western blot for TIP30, eEF1A1, and Actin in TIP30 Het mice 6 after TAC surgery and their quantification (N = 4 mice/group).
I, J Western blot for TIP30, eEF1A1, and Actin 2 weeks after sham or TAC surgery in AAV-Con or AAV-TIP30-treated C57BL/6 WT mice and their quantification
(N = 4 mice/group).
Data information: Data are shown as mean  SEM. A ratio of TIP30 and eEF1A1 expression was calculated for each condition. *P < 0.05, **P < 0.01, ***P < 0.001, and
****P < 0.0001. Two-sided Student’s t-test.
Source data are available online for this figure.
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TIP30 during PE administration produced a profile characterized by
accumulation of 80S ribosomes and a depletion of polysomes. This
profile is compatible with inhibition of protein synthesis either at a
late step in translation initiation or early in elongation (Schneider-
Poetsch et al, 2010). To decipher this further, we transfected
cardiomyocytes with a luciferase plasmid that reports cap-depen-
dent translation (dependent on functional translational initiation) as
renilla luciferase activity and cap-independent translation (i.e., not
dependent on functional translation initiation) as firefly luciferase
activity (Fig EV4C). In this assay, both renilla and firefly luciferase
activities were similarly induced by PE stimulation in control
cardiomyocytes and were similarly inhibited by TIP30 overexpres-
sion (Fig EV4D and E). This indicated that TIP30 primarily inter-
feres with translational elongation, because inhibition of
translational initiation would have reduced selectively only the
renilla signal. A 2D-Gel-based comparative proteomic analysis
(DIGE) of cardiomyocytes during PE stimulation with and without
TIP30 overexpression did not show selective inhibitory effects of
TIP30 on the abundance of specific proteins (Appendix Table S3),
supporting a role of TIP30 as a general inhibitor of protein synthe-
sis. Furthermore, inhibition of protein synthesis by TIP30 overex-
pression during TAC induced hypertrophy in vivo was confirmed by
assessment of cardiac puromycin incorporation (Fig EV4F and G).
Next, we assessed protein synthesis in mice with reduced TIP30
levels compared to WT mice. Puromycin labeling indicated
enhanced protein synthesis in Het mice, but not KO mice 3 days
after TAC (Fig EV5A). Because cardiac overload puts an increased
demand on the protein folding capacity of the endoplasmic reticu-
lum (ER), we assessed whether the unfolded protein response
(UPR) was initiated due to ER-stress (Arrieta et al, 2018). We found
that the adaptive UPR response genes Hrd1, Xbp1, and Manf were
significantly upregulated in the homozygous TIP30 KO mice after
TAC, while only a trend was visible in Het mice after TAC. Rheb
was upregulated in both genotypes after TAC, but more significantly
in homozygous KO mice (Fig EV5B).
Hence, increased TIP30 levels inhibited cardiomyocyte protein
synthesis, while reduced levels of TIP30 predisposed to increased
myocardial protein synthesis during hypertrophic stimulation. Espe-
cially in homozygous TIP30 KO mice, pathological overload is asso-
ciated with activation of the UPR.
The anti-hypertrophic role of TIP30 depends on eEF1A
To establish a direct link between eEF1A and cardiomyocyte hypertro-
phy, we used narciclasine, which acts as inhibitor of eEF1A (Van
Goietsenoven et al, 2010). Neonatal mouse cardiomyocytes of Het
mice exerted more hypertrophy (measured as cell size) compared to
WT cells during pro-hypertrophic ET-1 stimulation, but this was
completely blunted by narciclasine, suggesting that the enhanced
growth of Het cardiomyocytes depended on functional eEF1A (Fig 7C).
Even more importantly, narciclasine treatment of WT and Het mice
during 2 weeks of pressure overload also blunted increased hypertro-
phy (measured as HW/TL, wall thickness, and cardiomyocyte area) in
Het versus WT mice in vivo (Fig 7D–G). At the same time, narciclasine
markedly improved cardiac function after TAC in Het mice compared
to untreated Het mice (Fig 7H). Myocardial puromycin incorporation
was enhanced in the myocardium of Het versus WT mice after TAC
(again showing increased myocardial protein synthesis), and this effect
was blunted in Het mice receiving narciclasine (Fig 7I).
Finally, we determined whether the effects of TIP30 overexpression
depended on eEF1A1: siRNA-mediated eEF1A1 downregulation
reduced the anti-hypertrophic effects of overexpressed TIP30 in PE-
treated cardiomyocytes (Fig EV5C and D). Similarly, eEF1A inhibition
by narciclasine reduced PE-driven cardiomyocyte hypertrophy and
strongly ameliorated the growth inhibitory effects of TIP30 expression
during PE stimulation (Fig EV5E). Accordingly, while recombinant
◀ Figure 6. The TIP30/eEF1A1 ratio decreases in human failing and hypertrophic cardiomyopathy hearts.A–C Quantification of Tip30 and eEF1A1 mRNA transcript abundance in human failing hearts, N = 6–8 hearts/group (A), in patients with hypertrophic cardiomyopathy
(HCM; B, N = 4–8 hearts/group) and 6-month-old mdx mice or WT mice, N = 4 mice/group (C). A ratio of Tip30 and eEF1A1 expression was calculated for each
condition. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. Two-sided Student’s t-test.
D Schematic representation of AAV-study design in mdx (MDX) mice.
E Echocardiographic diastolic left ventricular wall thickness in MDX mice at the age of 2 months at baseline, and 1–9 months (mo) after injection of AAV9-Con or
AAV9-TIP30 (TIP; N = 6–7 mice/group). *P < 0.05, **P < 0.01. One-way ANOVA with Sidak’s multiple comparisons test.
F Quantification of HW/TL ratio of 9-month-old MDX mice, N = 5–6 mice/group. *P < 0.05. Two-sided Student’s t-test.
Data information: Data are shown as mean  SEM.
▸Figure 7. TIP30 inhibits protein synthesis in cardiomyocytes.A Western blot analysis of isolated neonatal rat cardiomyocytes (NRCM) after adenoviral transduction either with control adenovirus (Con) or Ad.TIP30 (TIP30)
followed by stimulation with phenylephrine (PE, for 3 h) and puromycin incorporation (for 30 min).
B Quantification of the Western blot shown in (A) (N = 3 samples/group). *P < 0.05, **P < 0.01. One-way ANOVA with Sidak’s multiple comparisons test.
C Quantification of cell surface area of isolated neonatal mouse cardiomyocyte of Tip30 Het and WT mice treated with endothelin-1 (ET-1) and narciclasine (Narci)
or without stimulation as indicated (N = 6 samples/group). *P < 0.05, ***P < 0.001. One-way ANOVA with Sidak’s multiple comparisons test.
D Schematic representation of narciclasine study design.
E–H Quantification of HW/TL ratio, N = 6–10 mice/group (E), echocardiographic wall thickness, N = 6–10 mice/group (F), cardiomyocyte area, N = 5 mice/group (G), and
fractional area change (FAC, H, N = 6–10 mice/group) in Tip30 Het or WT mice 2 weeks after TAC. Animals were treated with narciclasine daily for 14 days after
TAC as indicated. *P < 0.05, **P < 0.01, ***P < 0.001. One-way ANOVA with Sidak’s multiple comparisons test.
I Western blot analysis of puromycin incorporation in hearts of Tip30 Het and WT mice 3 days after TAC or sham surgery and daily narciclasine (Narci) injection and their
quantification (N = 2–4mice/group). Puromycin was injected 3 h prior to sacrifice. *P < 0.05, **P < 0.01. One-way ANOVA with Sidak’s multiple comparisons test.
Data information: Data are shown as mean  SEM.
Source data are available online for this figure.
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full-length TIP30 blocked translation of a renilla-reporter mRNA in
rabbit reticulocyte lysate in vitro, a mutant TIP30 (lacking the N-term-
inal 52 amino acids) devoid of eEF1A1 binding capability, did not
significantly inhibit translation in this system (Fig EV5F).
Discussion
In this study, we found that TIP30 restricts protein synthesis and
hypertrophy in cardiomyocytes at the level of translational elongation
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by binding to eEF1A1, inhibiting the interaction with its GEF eEF1B2,
and thereby reducing the generation of active GTP-bound eEF1A1.
While according to our model a balanced abundance of TIP30 and its
target eEF1A1 enables compensated cardiac growth during pathologi-
cal overload, a reduced myocardial TIP30/eEF1A1 ratio like in the late
stage of human heart failure promotes exaggerated cardiomyocyte
growth and ventricular dysfunction, which could arise from insuffi-
cient concomitant myocardial capillary growth. Indeed, heterozygous
TIP30 knock-out mice with similarly reduced TIP30 protein levels as
we observed in human heart failure, developed enhanced hypertro-
phy, myocardial capillary rarefaction, and systolic ventricular
dysfunction. Overexpression of TIP30 in a cardiomyopathy mouse
model with diminished cardiac TIP30 levels, in turn, ameliorated
pathological hypertrophy and improved contractility. Besides in heart
failure, downregulation of TIP30 was reported previously in aggres-
sive forms of cancer (Ito et al, 2003; Zhao et al, 2007; Li et al, 2009;
Tong et al, 2009). Not unlike in the heart, reduced TIP30 levels are
associated with accelerated growth, cell transformation, and
enhanced metastasis formation in human tumors (Ito et al, 2003;
Zhao et al, 2007; Li et al, 2009; Tong et al, 2009).
We were initially surprised by the fact that heterozygous Tip30
knock-out mice exerted a stronger cardiac phenotype compared to
homozygous KO mice. Quite similarly, however, Het mice also
develop more tumors than homozygous KO mice, indicating that
TIP30 is haploinsufficient for tumor suppression and for the
suppression of heart growth, i.e., that even a reduction of TIP30
levels by about 50% triggers disease (Ito et al, 2003). We hypothe-
size that the complete lack of TIP30 in KO mice induces compen-
satory mechanisms early during development, which partially
ameliorate the consequences of the absence of TIP30. One such
mechanism could involve the stronger induction of the UPR as
adaptive ER response in homozygous KO mice, which might in part
improve heart function during pathological stress by restoring
protein homeostasis (Arrieta et al, 2018; Blackwood et al, 2019;
Wang et al, 2019). It will be interesting to further decipher the
nature of these compensatory mechanisms in future studies,
because they might inherit therapeutic potential for hypertrophic
heart disease.
Protein synthesis is the main driver of cellular growth, and
when cells reach a certain size, mitosis is initiated (Fenton & Gout,
2011). Since adult cardiomyocytes exit cell cycle shortly after birth,
hypertrophy is the natural mode of growth in these cells (Heineke
& Molkentin, 2006; Hill & Olson, 2008). Indeed, increased protein
synthesis has been found to underlie hypertrophic growth during
pressure overload in different species (Nagai et al, 1988; Imamura
et al, 1994; Nagatomo et al, 1999). Cardiac mechanical overload
triggers enhanced mRNA translation within the first days after it
has emerged (Ivester et al, 1995). Exactly within that time frame
of rapid cardiac growth (in our study at day 3 after surgery),
reduced TIP30 levels in Tip30 Het mice led to increased eEF1B2/
eEF1A1 association and protein synthesis in response to TAC, indi-
cating that it acts to prevent an overshooting increase in transla-
tion and cell growth under these circumstances. TIP30
downregulation or overexpression did not affect cardiomyocyte or
cardiac growth without pro-hypertrophic stimulation (e.g., under
sham conditions) when short time points were analyzed. We
propose that under these conditions, TIP30 only inhibits the low
levels of homeostatic protein synthesis that are present in
cardiomyocytes not actively growing. Consequently, the effects of
TIP30 are not immediately visible, but become important over
longer time periods, such as in Tip30 Het mice, which exert
increased heart growth at 7 months of age.
How does TIP30 regulate translation? Unlike, for example, in
lung adenocarcinoma cells, where TIP30 directly influences intra-
cellular signaling, this was not apparent in cardiomyocytes (Zhang
et al, 2011a; Li et al, 2013). We rather found that TIP30 associates
with the elongation factor eEF1A. Our results indicate that TIP30
binds eEF1A1 at its middle domain, where also aminoacyl-tRNAs
and its GEF eEF1B2 interact (Sasikumar et al, 2012). While tRNA
binding occurred unabated by TIP30, eEF1B2 binding to eEF1A1
was blocked by increased and enhanced by reduced TIP30 concen-
trations. Since the eEF1B2/eEF1A1 interaction, which was
strengthened during cardiomyocyte hypertrophy, is crucial for the
propagation of translation (Pittman et al, 2009), abrogation of this
interaction by TIP30 will stall translational elongation. The regula-
tion of translation at the level of the interaction between eEF1A1
and eEF1B2—like we show here for TIP30—has been previously
demonstrated as the result of eEF1B2 phosphorylation by the cell
cycle-dependent kinase (CDK)1 leading to reduced interaction with
eEF1A1 and downregulation of translation during mitosis (Sivan
et al, 2011; Sasikumar et al, 2012). Reduced activation of transla-
tion due to decreased eEF1A1 activity leads to diminished cell
proliferation or cell growth in different cell types (Kim et al, 2009;
Lin et al, 2010; Belyi et al, 2012). Remarkably, TIP30 appears to
act on protein synthesis independent of mTORC1, which was even
de-activated in a counter-regulatory manner in TIP30-deficient
mice.
We found in this study that TIP30 interacts with both isoforms of
eEF1A (eEF1A1 and eEF1A2), which are 92% identical at the amino
acid levels and which are thought to fulfill similar functions in the
regulation of translational elongation (Abbas et al, 2015). We there-
fore propose that TIP30 acts on both isoforms in a similar manner,
although in this study we primarily characterized its effects on
eEF1A1. Notably, although eEF1A1 became down- and eEF1A2
upregulated in the myocardium after birth as previously described
(Chambers et al, 1998), eEF1A1 was strongly re-induced in response
to pressure overload. Thus, like in certain forms of cancers, the
heart expresses both eEF1A isoforms during overload (Abbas et al,
2015). Together, we suggest a new paradigm, whereby cardiomy-
ocyte hypertrophy can be targeted at the level of translational
elongation through interference with eEF1A, for example, via over-
expression of TIP30 or through substances like narciclasine. Indeed,
narciclasine reduced hypertrophy in wild-type rat cardiomyocytes
and Het mouse cardiomyocytes in vitro as well as in Het mice
in vivo, although an effect on protein synthesis and heart growth in
wild-type mice in vivo was not observed here, likely due to insuffi-
cient dosing. Especially, since eEF1A is being investigated as novel
anti-cancer target (Abbas et al, 2015), some of the findings from
these studies might be transferable toward the treatment of heart
failure in the future.
Materials and Methods
All mice, reagents, antibodies, plasmids, oligonucleotides, and kits
used in this study are summarized in Appendix Table S4.
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Human heart samples
Control tissue was from victims of traffic accidents or from healthy
heart organ donors, when the organ was ineligible for transplanta-
tion. Samples from failing hearts were derived from patients with
ischemic (n = 2) or dilated cardiomyopathy (n = 7) undergoing
cardiac transplantation (Haq et al, 2001). Samples from patients
with hypertrophic cardiomyopathy (Appendix Table S2) were
acquired during myectomy or cardiac transplantation. Their use was
permitted by the Massachusetts General Hospital Institutional
Review Board (USA), and by the Ethical Committee of the Hannover
Medical School, Germany (Az. Z 14.06-A 1871-30724/98 and 2276-
2014). Informed consent was obtained from all subjects. The experi-
ments conformed to the principles set out in the WMA Declaration
of Helsinki and the Department of Health and Human Services
Belmont Report.
Mouse models
Tip30 knock-out mice were in a FVBN background and have been
described previously (Ito et al, 2003). Breeding pairs were a gener-
ous gift by H. Xiao (Department of Physiology, Michigan State
University, USA). Male Tip30 WT, Het, and KO mice at 6–8 weeks
of age were used for experiments. The mdx mice were previously
described (Schinkel et al, 2012). AAV9-treated mice used in this
study were male C57BL/6N wild-type mice (Charles River Laborato-
ries) as well as mdx mice and Tip30 Het mice at the age of 6 weeks.
The animals had free access to water and a standard diet and were
maintained on a 12-h light and dark cycle at a room temperature of
22  2°C. For rescue experiments after TAC, narciclasine (#sc-
361271, Santa Cruz) was injected into Tip30 Het mice and WT litter-
mate controls daily for 14 days (1 lg/g BW i.p.). Premature death
was a criterion for exclusion from an ongoing experiment. Death
rates were not significantly different between experimental TAC
groups in this study. All procedures involving the use and care of
animals were performed according to the Guide for the Care and
Use of Laboratory Animals published by the National Research
Council (NIH Publication No. 85-23, revised 1996) and the German
animal protection code. Approval was granted by the local state
authorities (3.9-42502-04-10/0269 and 33.12-42502-04-15/1871).
Aortic banding
Transverse aortic constriction (TAC) or sham surgery was
performed in 8-week-old mice by subjecting the aorta to a defined
25 gauge constriction as described (Zwadlo et al, 2015).
Transthoracic echocardiography and cardiac catheterization
For echocardiography, mice were anaesthetized with 0.5–1.0%
isoflurane and placed on a heating pad to maintain body tempera-
ture. Non-invasive, echocardiographic parameters were measured
with a linear 30 MHz transducer (Vevo 770, Visualsonics). LV end-
diastolic area (LVEDA) and end-systolic area (LVESA) were
recorded. Fractional area change was calculated as [(LVEDA 
LVESA)/LVEDA] × 100. Intraventricular pressures in mice were
assessed in anesthetized (2% isoflurane) and artificially ventilated
(MiniVent respirator, Harvard Apparatus) mice using a 1F microtip
pressure–volume catheter (PVR 1045, Millar Instruments) coupled
with a Powerlab/4SP acquisition system (ADInstruments Ltd), as
described (Zwadlo et al, 2015). Cardiac parameters were recorded
using LabChart (ADInstruments Ltd.) to calculate end-systolic and
end-diastolic pressure and heart rate. The hemodynamic measure-
ments in mdx mice were made in closed-chest, spontaneously
breathing mice. Mice were anaesthetized by intraperitoneal injection
of medetomidine (0.5 lg/g body weight), fentanyl (0.05 lg/g body
weight), and midazolam (5 lg/g body weight). A 1.2 Fr catheter
(Model FT111B Scisense Inc., London, ON, Canada) was inserted
into the left ventricle of the mouse through the carotid artery to
simultaneously measure pressure and volumes. Left ventricular
volumes were extrapolated from admittance magnitude and admit-
tance phase in real time using the ADVantage PV system (Scisense
Inc.). Pressure and volume data were recorded using a Scisense
404—16 Bit Four Channel Recorder with LabScribe2 Software
(Scisense Inc.). Transient inferior vena cava compressions were
applied to reduce preload and determine end-systolic elastance
(Ees). After baseline measurement, intraperitoneal injection of dobu-
tamine with a dose of 20 ng/g body weight was performed and
hemodynamic measurements were repeated 5 min after injection.
Doppler velocity measurements
Following echocardiography, the flow velocity signals of the right
carotid artery (RCA) and the left aortic artery (LCA) were measured
by placing the Doppler-probe [20 MHz probe of INDUS instruments
(version 1.7)] on the right or left side of the cervical midline, respec-
tively (Hartley et al, 2011).
AAV9-mediated overexpression of TIP30
The open reading frame of the Tip30 gene was cloned into the AAV-
vector genome plasmid pds-CMVenh-MLC260 or pdsTnT-Cre, respec-
tively. For production of AAV9-TIP30 pseudotyped vectors, these plas-
mids were used for co-transfection of HEK293T cells together with
pDP9rs, a derivate of pDP2rs encoding the AAV9 cap sequence, the
AAV2 rep gene, and adenoviral helper sequences. For generation of the
control vector AAV9-rLuc (AAV9-control), a vector genome plasmid
with Renilla luciferase was used. AAV vectors were produced, purified,
and titrated using standard procedures (Werfel et al, 2014). AAV9
vectors were administered into the tail vein of 6-week-old male C57BL/
6N mice (5 × 1011 vg/ml in PBS) or Tip30 Het mice (2 × 1011 vg/ml in
PBS) 2 weeks prior to TAC and at the age of 2 months in mdx mice.
Measurement of translation rates in vivo
To assess global translation rates in mice, the incorporation of puro-
mycin in actively translated proteins of the heart was measured.
Puromycin (Sigma) was injected intraperitoneally (25 mg/kg body
weight) into mice 3 days after TAC 3 h prior to sacrifice.
Primary cardiomyocytes cultures
Neonatal cardiomyocytes were isolated from 1- to 3-day-old
Sprague-Dawley rats by Percoll density gradient centrifugation as
previously described (Zwadlo et al, 2015). Isolated neonatal rat
cardiomyocytes (NRCM) were stimulated with either phenylephrine
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(20 lM), fetal bovine serum (2%), or endothelin-1 (100 nM) for
48 h to induce hypertrophy. To measure incorporation of puro-
mycin into actively translated proteins 24 h after adenoviral trans-
duction and 3 h of PE stimulation, puromycin (0.1 lg/ml, Sigma)
was added into NRCM cell culture for 30 min prior to collecting cell
lysates for Western blot analyses. To inhibit eEF1A function, NRCM
were incubated with the specific inhibitor narciclasine (100 nm,
Santa Cruz) for 24 h as indicated.
To generate Ad.TIP30, rat Tip30 ORF (NM_001106263.2) was
cloned into pShuttleCMV. Virus production was carried out with the
AdEasy Adenoviral Vector Systems Kit from Agilent following the
protocol. NRCM were transduced the day after isolation. If needed,
cells were transfected with siRNA directed against eEF1A1
(SASI_Rn02_00269532, Sigma-Aldrich) or siControl (AM4611,
Ambion) using Lipofectamine 2000 (Thermo Fisher Scientific)
according to the manufacturer’s protocol. Adult cardiac myocytes
(ARCMs) were isolated according to AfCS Procedure Protocol ID
PP00000125 (http://www.signaling-gateway.org/data/ProtocolLinks.
html). Cell size of NRCM and ARCM was measured of at least 100
myocytes per culture dish or mouse using a Zeiss AxioObserver.Z1
Inverted Microscope (Zeiss) and ImageJ (http://rsb.info.nih.gov/ij/).
For analysis of protein/DNA ratio, NRCM were pelleted, resuspended
in lysis buffer (10 mM Tris, 150 mM NaCl, 4% glycerol, 0.5 mM
sodium metabisulfite, 1% Triton X, 0.1% sodium deoxycholate,
0.05% SDS, pH 7.5), and split into aliquots for DNA and protein
measurement.
Protein was measured using Micro BCA Protein Assay Kit
(Thermo Fisher Scientific) according to the manufacturer’s protocol.
DNA content was measured using Hoechst 33258 reagent (Sigma-
Aldrich) with calf thymus DNA as a standard (Life Technologies). In
brief, NRCM suspensions were added to buffer containing 10 mM
Tris, 2 M NaCl, 1 mM EDTA, pH 7.4, and 100 ng/ml Hoechst 33258
reagent. Fluorescence was measured using a Modulus Luminometer
(Turner BioSystems) at excitation and emission wavelengths of 365
and 460 nm, respectively.
Measurements of cell contractility and sarcomere length in
isolated adult mouse myocytes
Following isolation, ventricular myocytes were placed on 3-cm dishes
(#P35G-1.5-10-C, MatTek) coated with laminin (10 mg/cm2) and
were washed 3 h later with MEM medium. The isolated myocytes
were then transferred to the recording chamber of the IonOptix
System. Sarcomere shortening was assessed upon field stimulation
(1, 2 and 4 Hz) using a video-based sarcomere length detection
system (IonOptix Corporation) at 37°C. The recordings were subse-
quently analyzed with the Ion Wizard software (IonOptix).
Quantitative real-time PCR
Total RNA was extracted using TriFast (Peqlab). cDNA was synthe-
sized from 1 lg RNA using Maxima H Minus First Strand cDNA
Synthesis Kit (Thermo Fisher Scientific), and quantitative real-time
PCR was performed using SYBR Green (Thermo Fisher Scientific) on
a MX4000 multiplex QPCR system (Stratagene). Transcript quanti-
ties were normalized to GAPDH mRNA with three exceptions where
ribosomal protein L7 for normalization of a- and ß-MHC expression
(Fig 1H and I) and of Acta1 expression (Fig 2D) was used.
Immunoblot analysis
For immunoblot (Western blot) analysis, heart samples and isolated
cardiac myocytes were lysed in ice-cold lysis buffer (10 mM Tris,
150 mM NaCl, 4% Glycerol, 0.5 mM sodium metabisulfite, 1%
Triton X, 0.1% sodium deoxycholate, 0.05% SDS, pH 7.5). Equal
amounts of total protein were separated on SDS–polyacrylamide gel
electrophoresis under reducing conditions. Densitometry of protein
bands was performed using Quantity One software (Bio-Rad).
Immunostaining
For visualization of specific protein localization in NRCM, cells were
stained for anti-TIP30 (#ab177961, Abcam, 1:100) followed by Anti-
Rabbit IgG Alexa Fluor 488 secondary antibody (#4412, NEB,
1:250) and mouse monoclonal anti-eEF1A1 (#sc-21758, Sigma,
1:100) followed by Anti-Mouse IgG Alexa Fluor 555 secondary
antibody (#4409, NEB, 1:250). A goat polyclonal anti-PDGFRa
(#AF1062, R&D Systems, 1:100) antibody was used to label cardiac
fibroblasts. For visualization of specific protein localization in heart
tissue sections after AAV9-TropT-TIP30 transduction, these were
stained for anti-TIP30 (#ab71752, Abcam, 1:50) followed by Anti-
Rabbit IgG Alexa Fluor 555 secondary antibody (#4409, Cell Signal-
ing, 1:200) together with FITC-conjugated WGA (#L4895, Sigma-
Aldrich). Nuclear staining was performed with VECTASHIELD
Mounting Medium (Vector Laboratories) with DAPI. Representative
images were acquired using confocal microscopy. Confocal imaging
was performed with a TCS SP2 AOBS scan head and an inverted
Leica DM IRB microscope equipped with a 63× oil immersion objec-
tive. Image analysis was performed using ImageJ.
Co-immunoprecipitation
After crosslinking with 0.5% PFA/PBS for 5 min and quenching two
times with 1.25 M glycine/PBS, cells were lysed in binding buffer
(20 mM HEPES pH 7.6, 75 mM NaCl, 0.1% NP-40) supplemented
with protease inhibitors (Complete Protease Inhibitor Cocktail,
Roche). Lysates were incubated with indicated antibodies or IgG
controls overnight at 4°C, incubated with Protein A/G Plus Agarose
(Santa Cruz Biotechnologies), washed two times with binding
buffer, and resolved using Western blot analysis.
Proximity ligation assay
Proximity ligation assays were performed in isolated neonatal rat or
adult mouse cardiomyocytes using the Duolink In Situ Kit (Olink
Bioscience) according to the manufacturer’s instructions. Cells were
either stained for anti-TIP30 (#ab177961, Abcam, 1:100) and anti-
eEF1A1 (#sc-21758, Santa Cruz, 1:100) or anti-eEF1A1 (#ab118703,
Abcam, 1:100) and anti-eEF1B2 (#ab77043, Abcam, 1:100). Control
cells were stained for anti-TIP30 (#ab177961, Abcam, 1:100) and
anti-Myc (#2276, Cell Signaling, 1:100).
Electron microscopy
Whole hearts of TIP30 WT and Het mice were perfused and fixed in
150mM HEPES buffer, pH 7.35, containing 1.5% paraformaldehyde
and 1.5% glutaraldehyde over night. 2-mm cubes of heart tissue
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were then washed in 0.15 M HEPES buffer (2 × 6 min) and 0.1 M
cacodylate buffer, pH 7.35 (4 × 6 min), postfixed in 1% osmium
tetroxide in cacodylate buffer (2 h), followed by washing steps
(4 × 5 min cacodylate buffer, 2 × 5 min water) and 4% aqueous
uranyl acetate (over night at 4°C). The heart tissue was then washed
in water (2 × 5 min), dehydrated in acetone, and embedded in
Epon. 50-nm sections were poststained with 4% uranyl acetate and
lead citrate. Electron microscopic examinations were performed by
a blinded observer with a FEI Morgagni 268 transmission electron
microscope (FEI, Eindhoven, Netherlands) operated at 80 kV using a
Veleta CCD camera (Olympus Soft Imaging Solutions).
Tissue sampling
Excised hearts were arrested in diastole and either embedded in
OCT (Tissue-Tek, Sakura) or snap-frozen in liquid nitrogen for
further analysis. Hearts in OCT were sectioned at 12 lm thickness
and stained with Sirius red according to general protocols to detect
collagen fibers. For immunostaining slides were sectioned at 7 lm
thickness.
Luciferase reporter assay
Cell lysates were subjected to a Renilla Luciferase Assay System
(Promega) according to the manufacturer’s protocol. In brief, 1 day
after adenoviral transduction NRCM were transfected with a Renilla
luciferase plasmid using GeneTrans II Transfection reagent
(MoBiTec). After 48 h, cells were either subjected to a luciferase
reporter assay or RNA was isolated for subsequent quantitative real-
time PCR. Luciferase activity was detected by using a Modulus
Luminometer (Turner BioSystems) and normalized to total protein
concentration.
Cell death assays
To analyze cell death rates, NRCM were transduced with Ad.Control
or Ad.TIP30 adenovirus, stimulated with PE for 48 h, washed with
1× PBS, and incubated with 7-AAD (Annexin V: PE Apoptosis Detec-
tion Kit I, BD Biosciences) 1:400 in 1× PBS for 15 min. After fixation
with 100% ethanol, cells were mounted with VECTASHIELD Mount-
ing Medium (Vector Laboratories) with DAPI. Tissue staining of
cleaved caspase-3 (CC3), the activated form of caspase-3, was done
with rabbit polyclonal anti-Cleaved Caspase-3 (Asp175, #9661, Cell
Signaling, 1:100) using standard procedures.
In vitro translation
In vitro translation reactions were performed in Flexi rabbit reticulo-
cyte lysate (Promega) using 50 ng Renilla mRNA as template follow-
ing the manufacturer’s protocol. Purified His-tagged proteins and
BSA as control were added in the indicated amounts. The result of
translation was analyzed with the Renilla luciferase assay supplied
with the reticulocyte lysate.
Plasmids
The open reading frames of rat Tip30 (NM_001106263.2), rat
eEF1A1 (BC128723.1), and rat eEF1B2 (NM_001108799.2) were
cloned into the pcDNA3.1/V5-His A vector (Life Technologies) to
generate His6-Tag fusion proteins and into the pGEX-4T1 vector (GE
Healthcare) to generate GST-Tag fusion proteins. Large deletion
mutants of TIP30 as well as eEF1A1 were generated by cloning
single fragments of the open reading frames into the indicated
vectors. The open reading frames of rat Ncl (coding for nucleolin;
BC085751.1), rat Rps3a (coding for 40S ribosomal protein S3a;
BC058483.1), and human hnRNPA2/B1 (XP_003689535.1) were
cloned into pShuttleCMV (Agilent) with a Myc-tag epitope inserted
at the C-terminus by PCR.
Cell culture and transfection of cells
HEK293 and COS-1 cell lines were grown in Dulbecco’s modified
Eagle medium (DMEM) 4.5 g/l glucose w/o glutamine (Pan-
Biotech) supplemented with 10% (v/v) of FBS (ATCC) and 1%
(v/v) of Penicillin/Streptomycin solution (Pan-Biotech) at a temper-
ature of 37°C in the presence of 5% of CO2. Cells were plated in 6-
well plates and transfected with Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s protocol with 1 lg of plasmid DNA.
Cells were incubated for 48 h to ensure protein expression.
Protein purification
His6-tagged proteins were expressed in indicated cell lines and puri-
fied with Ni-NTA Spin columns (Qiagen) under native conditions
according to manufacturer’s protocol. Purified proteins were imme-
diately subjected to Zeba Spin desalting columns (7K MWCO,
Thermo Fisher Scientific) to exchange imidazole-containing elution
buffer into PBS.
GST-pulldown assay
GST-tagged proteins were expressed in Escherichia coli BL21 (DE3).
The purified proteins were bound to glutathione agarose beads
(Thermo Fischer Scientific) and incubated for 2 h at 4°C with whole
cell lysates or purified proteins as indicated. After washing two
times with PBS, bound proteins were eluted by heating the
glutathione beads at 95°C for 5min in SDS loading buffer and
detected by Western blot analysis.
Identification of protein interaction partners after
GST-pulldown assay
A GST-pulldown assay was performed with GST or GST-TIP30 from
neonatal rat cardiomyocyte lysate. Bound proteins were loaded on a
SDS–PAGE under reducing conditions. Protein bands that were
apparent only in the GST-TIP30 pulldown lane were excised and
identified by mass spectrometry.
DIGE (difference in-gel electrophoresis) analysis
NRCM were infected with Ad.Control or Ad.TIP30 and were treated
with PE (20 lM) on the following day for 24 h. The cells were
harvested in DIGE lysis buffer (8 M urea, 30 mM Tris, 4% (w/v)
CHAPS) with protease inhibitors (Complete Protease Inhibitor Cock-
tail, Roche). After the determination of protein concentrations, fluo-
rescent dye labeling reactions (GE Healthcare) were conducted and
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20 lg of protein was subjected to two-dimensional gel electrophore-
sis. Three gels per condition were analyzed. Protein spots with more
than 1.2-fold significant (P < 0.05) difference in abundance between
the two conditions were identified by mass spectrometry.
tRNA binding assay
HEK cells were lysed 48 h after DNA transfection with pcDNA3.1/
V5-eEF1A1-His in lysis buffer (50 mM NaH2PO4, 300 mM NaCl,
10 mM imidazole, 1% Tween). The cell lysate was incubated with
Ni-NTA Magnetic Agarose Beads (#36113, Qiagen) according to the
manufacturer’s protocol. Beads with bound eEF1A1-His were then
washed two times with GTP Binding Buffer (25 mM Tris–HCl pH
7.4, 10% glycerol, 75 mM NaCl, 1 mM Na3VO4, 5 mM NaF, 5 mM
b-glycerophosphate, 0.025% Triton X) to remove endogenous
bound GDP from eEF1A1. This was followed by incubation with
isolated recombinant TIP30-His or BSA as control in indicated
concentrations in GTP Binding Buffer. After 30 min, GTP (#A1803,
AppliChem) was added to a final concentration of 17 mM and incu-
bated again for 30 min. Finally, 0.5 ll FluoroTectTM GreenLys tRNA
(#L5001, Promega) was added. Beads were washed two times with
GTP Binding Buffer after 30 min of incubation, and bound eEF1A1-
His was eluted with Elution Buffer (50 mM NaH2PO4, 300 mM
NaCl, 500 mM imidazole). Fluorescence of eEF1A1 bound tRNA
was measured using a Modulus Luminometer (Turner BioSystems).
Representative images
Images of histological sections, immunofluorescence pictures,
Western blots, and GST-pulldown assays or immunoprecipitations
are representative images, and the respective experiments were
successfully repeated at least two times.
Statistics
Statistical analysis was performed using Prism 6 (GraphPad Soft-
ware). Data are shown as mean  standard error of the mean
(SEM). All experiments were carried out in at least three biological
replicates. No statistical method was used to predetermine sample
size. Sample size was chosen as a result of previous experience
regarding data variability in similar models and experimental set-
up. The experiments were not randomized. The investigators were
blinded for mouse genotype and treatment during surgeries,
echocardiography, cardiac catheterization, organ weight determina-
tion, and all histological and immunofluorescence quantifications.
The variance was comparable between groups, and normality was
assumed. Multiple groups were compared by one-way repeated-
measures analysis of variance (ANOVA) followed by Sidak’s multi-
ple comparisons test or by unpaired, two-sided Student’s t-test when
comparing two experimental groups. Differences were considered
significant when P < 0.05. Exact P-values and n-number for each
graph are shown in Appendix Tables S5 and S6.
Expanded View for this article is available online.
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The paper explained
Problem
The mammalian adult heart expands in size mainly as a result of
cardiac muscle cell growth due to enhanced protein synthesis. During
common human diseases such as chronic arterial hypertension, aortic
valve stenosis, but also inherited cardiomyopathies, exaggerated heart
growth (referred to as hypertrophy) is associated with the development
of heart failure and poor prognosis. Cardiac hypertrophy, however, is
not sufficiently addressed by current treatment strategies. We hypothe-
sized that endogenous negative regulators of protein synthesis exist in
the heart to prevent aggravated hypertrophy and that these regulators
could potentially be used for therapeutic purposes in the future.
Results
We found that the tumor suppressor gene TIP30 counteracts cardiomy-
ocyte growth by binding to the elongation factor 1A (eEF1A). eEF1A is
known to promote translation by delivering amino acids to the ribo-
somes. Our findings suggested that TIP30 through binding to eEF1A
reduces protein synthesis by interfering with the interaction between
eEF1A and its guanine nucleotide exchange factor eEF1B2, which keeps
eEF1A in its active state. Due to this mechanism, even only a reduction
of TIP30 by around 50% in heterozygous TIP30 knock-out mice led to
increased cardiac protein synthesis, hypertrophy, and cardiac dysfunc-
tion in response to pathological pressure overload. TIP30 overexpression,
in turn, improved heart function under these circumstances and inhib-
ited myocardial protein synthesis and hypertrophy.
Importantly, TIP30 levels in relation to its target eEF1A are mark-
edly downregulated in failing and cardiomyopathic human hearts,
which according to our findings leave eEF1A active and thereby
promotes cardiac hypertrophy and failure. Indeed, the phenotype of
heterozygous TIP30 knock-out mice during pressure overload could be
significantly ameliorated by inhibiting eEF1A with the substance
narciclasine. On the other hand, overexpression of TIP30 in cardiomy-
opathic mice with endogenous TIP30 downregulation potently
reduced hypertrophic heart growth over time.
Impact
We suggest that exaggerated translational elongation is maladaptive
during pathological overload. In this regard, reduced TIP30 levels and
more active eEF1A in failing hearts might be an interesting new ther-
apeutic target, which could be addressed, for example, by TIP30 over-
expression or eEF1A inhibition through substances like narciclasine.
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